基于二代测序技术探究食管鳞癌分子生物学特征及临床意义

doi:10.6040/j.issn.1671-7554.0.2019.650

摘要/Abstract

摘要： 目的利用二代测序技术(NGS)对基因突变频率进行分析,探究食管鳞癌(ESCC)基因突变特征,寻找潜在的靶向治疗和免疫治疗靶点。方法随机收集49例山东省立医院确诊的ESCC患者的石蜡肿瘤组织样本,进行DNA提取,采用Illumina HiSeq4000测序平台对416个肿瘤相关基因进行捕获测序,测序结果进行生物信息学分析。结果发现TP53基因突变频率最高,并发现了多个ESCC潜在治疗靶点。EGFR 19del突变率和扩增率均为4.08%,未见EGFR L858R突变及KRAS突变;HER2和MET基因扩增发生率均为2.04%;BRCA1/2基因失活突变率约为8.06%;另外,MSI阳性率约为4.76%。提示携带相关靶点突变的患者可能是靶向治疗或免疫治疗的潜在获益人群。结论通过高通量检测技术发现ESCC多个潜在治疗靶点,对患者临床治疗方案的制定有重要意义。

关键词: 食管鳞癌, 二代测序, 基因变异, 靶向治疗

Abstract: Objective To explore the potential molecular targets and gene mutation characteristics in esophageal squamous cell carcinoma(ESCC)by using next-generation sequencing. Methods DNA was extracted from tissue samples collected from 49 ESCC patients. The 416 cancer-relevant genes were sequenced with Illumina HiSeq4000 platform. The sequencing data were then subjected to bioinformatics analysis. Results TP53 was identified as the most frequently mutated gene, and multiple potential therapeutic targets were revealed. The mutation rate and amplification rate of EGFR 19del mutations were both 4.08%, while no EGFR L858R mutation or KRAS mutation was detected. The amplification rate of HER2 and MET were both 2.04%. The inactivating mutation rate of BRCA1/2 was 8.06%. The positive rate of MSI was 4.76%, indicating that ESCC patients with related target gene variations would potentially benefit from targeted therapies or immunotherapies. Conclusion Multiple potential therapeutic targets in ESCC are identified using next-generation sequencing, which can significantly guide personalized ESCC treatment.

Key words: Esophageal squamous cell carcinoma, Next-generation sequencing, Gene mutation, Targeted therapy

中图分类号:

R574

冯阿磊,董青,逄娇慧,殷嘉妮,李强,韩俊庆,杨哲. 基于二代测序技术探究食管鳞癌分子生物学特征及临床意义[J]. 山东大学学报 (医学版), 2019, 57(7): 80-85.

FENG Alei, DONG Qing, PANG Jiaohui, YIN Jiani, LI Qiang, HAN Junqing, YANG Zhe. Exploring molecular characteristics of esophageal squamous cell carcinoma based on next-generation sequencing[J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 80-85.

参考文献

[1] Kang X, Chen K, Li Y, et al. Personalized targeted therapy for esophageal squamous cell carcinoma[J]. World J Gastroenterol, 2015, 21(25): 7648-7658.
[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3] Chen XX, Zhong Q, Liu Y, et al. Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing[J]. Nat Commun, 2017, 8(1): 524.
[4] Chen J, Kwong DL, Cao T, et al. Esophageal squamous cell carcinoma(ESCC): advance in genomics and molecular genetics[J]. Dis Esophagus, 2015, 28(1): 84-89.
[5] Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data[J]. Cancer Discov, 2012, 2(5): 401-404.
[6] Gao J, Aksoy BA, Dogrusoz U, et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal[J]. Sci Signal, 2013, 6(269): pl1.
[7] Zhou C. Lung cancer molecular epidemiology in China: recent trends[J]. Transl Lung Cancer Res, 2014, 3(5): 270-279.
[8] Guo K, Wang WP, Jiang T, et al. Assessment of epidermal growth factor receptor mutation/copy number and K-ras mutation in esophageal cancer[J]. J Thorac Dis, 2016, 8(7): 1753-1763.
[9] Huang J, Fan Q, Lu P, et al. Icotinib in patients with pretreated advanced esophageal squamous cell carcinoma with EGFR overexpression or EGFR gene amplification: a single-arm, multicenter phase 2 study[J]. J Thorac Oncol, 2016, 11(6): 910-917.
[10] Petty RD, Dahle-Smith A, Miedzybrodzka Z, et al. Epidermal growth factor receptor copy number gain(EGFR CNG)and response to gefitinib in esophageal cancer(EC): Results of a biomarker analysis of a phase Ill trial of gefitinib versus placebo(TRANS-COG)[J]. J Clin Oncol, 2014, 32(15):4016.
[11] Perez EA, Romond EH, Suman VJ. et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831[J]. J Clin Oncol, 2014, 32(33):3744-3752.
[12] Kawakami H, Okamoto I, Okamoto W, et al. Targeting MET amplification as a new oncogenic driver[J]. Cancers(Basel), 2014, 6(3): 1540-1552.
[13] Ozawa Y, Nakamura Y, Fujishima F, et al. c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target[J]. BMC cancer, 2015, 15(1): 451.
[14] Zhu Y, Wu J, Zhang C, et al. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis[J]. Oncotarget, 2016, 7(43): 70113-70127.
[15] Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation(SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(9): 1274-1284.
[16] Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy(ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 390(10106): 1949-1961.
[17] Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer[J]. N Engl J Med, 2016, 375(22): 2154-2164.
[18] Robson M, Im S A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation[J]. N Engl J Med, 2017, 377(6): 523-533.
[19] Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation[J]. N Engl J Med, 2018, 379(8): 753-763.
[20] Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer[J]. J Clin Oncol, 2018, 36(8): 773-779.
[21] Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science, 2017, 357(6349): 409-413.
[22] Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial[J]. Lancet Oncol, 2017, 18(5): 631-639.
[23] Shah MA, Kojima T, Hochhauser D, et al. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study[J]. JAMA oncol, 2018.

相关文章 15

[1]	王福立,孙银萍,秦杰,荣建胜. DC-CIK细胞联合EGFR-TKI治疗35例老年晚期EGFR突变肺癌的效果[J]. 山东大学学报 (医学版), 2022, 60(7): 110-117.
[2]	安袁笑雪,杜以明,田甜,张一,薛玉文. 肺炎奴卡菌合并天美奴卡菌肺部感染1例报道并文献复习[J]. 山东大学学报 (医学版), 2022, 60(3): 59-63.
[3]	王婧,刘小转,许芳芳. 肝豆状核变性的ATP7B基因变异分析及产前诊断[J]. 山东大学学报 (医学版), 2022, 60(2): 32-36.
[4]	哈春芳,李茹月. 卵巢癌耐药机制与靶向治疗策略的研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 117-123.
[5]	焉传祝,王伟,纪坤乾,赵玉英. 线粒体与脑疾病[J]. 山东大学学报 (医学版), 2020, 1(8): 34-41.
[6]	陈安静,张训. 靶向小类泛素化修饰的胶质瘤治疗新策略[J]. 山东大学学报 (医学版), 2020, 1(8): 88-94.
[7]	黄楚栓, 周锐, 洪海都, 刘建博. 二代测序法诊断腺病毒重症肺炎1例[J]. 山东大学学报 (医学版), 2020, 58(12): 121-124.
[8]	王建祥,顾闰夏. 急性髓系白血病的靶向治疗进展[J]. 山东大学学报 (医学版), 2019, 57(7): 6-12.
[9]	王昭. 噬血细胞性淋巴组织细胞增多症治疗的临床研究新进展[J]. 山东大学学报 (医学版), 2019, 57(7): 44-49.
[10]	王海涛. 去势抵抗性前列腺癌精准治疗的研究进展[J]. 山东大学学报 (医学版), 2019, 57(1): 30-35.
[11]	闫素真,杜鲁涛,王丽丽,王传新. 血清lncRNA UCA1在食管鳞癌的表达及临床意义[J]. 山东大学学报 (医学版), 2018, 56(6): 41-46.
[12]	公孙鑫,辛钟伟,史墨,秦启明,姜斌,宋学敏,刘相燕. 黏蛋白1C亚基对食管癌细胞生物学行为的影响[J]. 山东大学学报 (医学版), 2018, 56(10): 86-92.
[13]	凌瑞,张聚良. 乳腺癌内分泌治疗的相关进展[J]. 山东大学学报 (医学版), 2018, 56(1): 27-31.
[14]	王殊,彭媛. 从2017年美国临床肿瘤学会大会报告看早期乳腺癌治疗加减法[J]. 山东大学学报 (医学版), 2018, 56(1): 17-21.
[15]	陈波,张磊. 2017年乳腺癌新辅助治疗进展[J]. 山东大学学报 (医学版), 2018, 56(1): 12-16.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed